Table 2.
Comparison between the clinical and paraclinical findings in anti-AK5 encephalitis patients with different outcomes.
| Characteristics | N (%) |
aP value | |
|---|---|---|---|
| Stabilization/improvement (N = 21) | Progressive decline (N = 9) | ||
| Male | 13/21 (61.9) | 8/9 (88.9) | 0.210 |
| Cognitive deficit | 21/21 (100.0) | 9/9 (100.0) | 0.999 |
| Psychiatric-behavior change | 20/21 (95.2) | 7/9 (77.8) | 0.207 |
| Seizure | 0/21 (0.0) | 4/9 (44.4) | 0.005 |
| Altered level of consciousness | 1/21 (4.8) | 3/9 (33.3) | 0.069 |
| Bilateral temporal lobe T2/FLAIR hyperintensities | 19/21 (90.5) | 7/9 (77.8) | 0.563 |
| Pleocytosis | 16/21 (76.2) | 7/9 (77.8) | 0.999 |
| Positive oligoclonal bands in CSF | 18/19 (94.7) | 5/6 (83.3) | 0.430 |
| Elevated tau protein level in CSF | 7/9 (77.8) | 5/5 (100.0) | 0.505 |
| Immunotherapy | 0.221 | ||
| First-line immunotherapy | 9/20 (45.0) | 6/8 (75.0) | |
| Second-line immunotherapy | 11/20 (55.0) | 2/8 (25.0) | |
The definitions of outcomes (progressive decline, stabilization and improvement) in anti-AK5 encephalitis patients depend on inherent descriptions in referred literature.
Abbreviations: AK5, anti-adenylate kinase 5; CSF, cerebrospinal fluid; FLAIR, fluid-attenuated inversion recovery.
a
Fisher's exact test.